Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Veralipride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 9/20 | 1.00 |
| ▸ | DRD3 | P35462 | 9/20 | 1.00 |
| ▸ | CA2 | P00918 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | CA9 | Q16790 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CA6 | P23280 | 2/20 | 1.00 |
| ▸ | CA5A | P35218 | 2/20 | 1.00 |
| ▸ | CA7 | P43166 | 2/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Veralipride SCHEMBL32682196 | 1.00 | DRD2 (1.00) | DRD2DRD3CA2DRD1CA9 | |
| Veralipride SCHEMBL1651287 | 0.98 | DRD2 (0.97) | DRD2DRD3CA2DRD1CA9 | |
| Veralipride SCHEMBL28832637 | 0.93 | DRD2 (0.86) | DRD2DRD3CA2DRD1CA9 | |
| Veralipride SCHEMBL13724251 | 0.89 | DRD2 (0.79) | DRD2DRD3CA2DRD1CA9 | |
| SCHEMBL10560929 | 0.87 | DRD3 (0.77) | DRD2DRD3CA2DRD1CA9 | |
| SCHEMBL10565197 | 0.86 | DRD3 (0.75) | DRD2DRD3CA2DRD1CA9 | |
| SCHEMBL10759082 | 0.86 | DRD3 (0.75) | DRD2DRD3CA2DRD1CA9 | |
| SCHEMBL10561820 | 0.86 | DRD3 (0.75) | DRD2DRD3CA2DRD1CA9 | |
| SCHEMBL10355478 | 0.85 | DRD2 (1.00) | DRD2DRD3CA2DRD1CA9 | |
| SCHEMBL27678962 | 0.85 | DRD2 (1.00) | DRD2DRD3CA2DRD1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2024107681-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-20240000810-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS | Orcosa Inc. (US) | 2024-01-04 | — | — | US | claimed |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-10-12 | — | — | US | claimed |
| EP-4192579-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | Response IP Holding Company, LLC (US) | 2023-06-14 | — | — | EP | claimed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022159507-A1 | COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| WO-2022032077-A2 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | REDUX THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| US-11123311-B2 | Methods of treating mental disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| US-20060045846-A1 | Reagents and methods for labeling terminal olefins | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-03-02 | — | — | US | claimed |
| WO-2005102366-A2 | LITHIUM COMBINATIONS, AND USES RELATED THERETO | SATOW PHILIP MAXWELL (US) | 2005-11-03 | — | — | WO | claimed |
| US-20050233010-A1 | Lithium combinations, and uses related thereto | NOVEN THERAPEUTICS, LLC | 2005-10-20 | — | — | US | claimed |
| EP-1121099-B1 | PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE | SANOFI SYNTHELABO (FR) | 2004-04-21 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| JP-2002527464-A | — | — | 2002-08-27 | — | — | JP | claimed |
| EP-1121099-A1 | PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE | SANOFI-SYNTHELABO (FR) | 2001-08-08 | — | — | EP | claimed |
| WO-2000051563-A1 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING A BENZAMIDE AND AT LEAST AN ABSORPTION PROMOTER | SANOFI-SYNTHELABO (FR) | 2000-09-08 | — | — | WO | claimed |
| WO-2000023045-A1 | PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE | SANOFI-SYNTHELABO (FR) | 2000-04-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | DRD2 2127/4885DRD3 2303/4885CA2 4132/4885 |
| US-20050233010-A1 | Lithium combinations, and uses related thereto | NPY4R, ADRA1D, HTR4 | DRD2 37/4885DRD3 31/4885CA2 1048/4885 |
| US-20230321073-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DYSREGULATION | LIPC, CPT1A, CETP | DRD2 4836/4885DRD3 4793/4885CA2 4236/4885 |
| US-11123311-B2 | Methods of treating mental disorders | FAAH, EPHX1, FAAH2 | DRD2 183/4885DRD3 258/4885CA2 3231/4885 |
| US-20060045846-A1 | Reagents and methods for labeling terminal olefins | EEF2, RNF168, REL | DRD2 689/4885DRD3 520/4885CA2 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.